Addition of Vadastuximab Talirine to 7 + 3 Induction Therapy for Newly Diagnosed AML: Phase Ib Dose-Escalation Trial

December 3-6, 2016; San Diego, California
Results from a phase Ib trial combining vadastuximab talirine to 7 + 3 induction therapy suggests deeper and more rapid remissions, without added nonhematologic toxicity, for patients with newly diagnosed AML.
Format: Microsoft PowerPoint (.ppt)
File Size: 432 KB
Released: December 5, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

Commentary from Jeff Sharman, MD, on noncovalent BTK inhibitors in patients with CLL and progression on currently available BTK inhibitors, from Clinical Care Options (CCO)

Jeff P. Sharman, MD Released: September 25, 2020

Interactive on-demand Webcast featuring expert insights on the newest data influencing best practice for managing patients with CLL

Farrukh T. Awan, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: September 24, 2020 Expired: September 23, 2021

Ian W. Flinn, MD, PhD; Shaji Kumar, MD; and Farhad Ravandi, MD, discuss important presentations in hematologic malignancies from the virtual ASCO 2020 as reported by Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Shaji Kumar, MD Farhad Ravandi, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 23, 2020 Expired: September 22, 2021

Commentary by Jesús F. San-Miguel, MD, PhD, on treating patients with myeloma who experience biochemical relapse from Clinical Care Options (CCO)

Jesús F. San-Miguel, MD, PhD Released: September 22, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue